Immune Response Corp. Plans Offering: The San...
- Share via
Immune Response Corp. Plans Offering: The San Diego biotechnology company co-founded by Jonas Salk, which is trying to develop an AIDS vaccine, has filed for permission to hold an 2.2-million-share initial public stock offering to raise as much as $19.8 million. Now in advanced clinical trials at several medical centers, the firm’s vaccine aims at stimulating patients’ immune response systems to prevent the disease from progressing to full-blown AIDS. The company had planned to go public last fall, but the offering was called off after the stock market soured.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
